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Abstract
Background: 5,10-Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in one-carbon metabolism that
ensures the availability of methyl groups for methylation reactions. Two single-nucleotide polymorphisms (SNPs) in
the MTHFR gene, 677C>T and 1298A>C, result in a thermolabile enzyme with reduced function. These variants, in
both the maternal and/or fetal genes, have been associated with pregnancy complications including miscarriage,
neural tube defects (NTDs), and preeclampsia (PE), perhaps due to altered capacity for DNA methylation (DNAm). In
this study, we assessed the association between MTHFR 677TT and 1298CC genotypes and risk of NTDs, PE, or
normotensive intrauterine growth restriction (nIUGR). Additionally, we assessed whether these high-risk genotypes
are associated with altered DNAm in the placenta.
Results: In 303 placentas screened for this study, we observed no significant association between the occurrence
of NTDs (N = 55), PE (early-onset: N = 28, late-onset: N = 20), or nIUGR (N = 21) and placental (fetal) MTHFR 677TT or
1298CC genotypes compared to healthy pregnancies (N = 179), though a trend of increased 677TT genotype in PE/IUGR
together was observed (OR 2.53, p = 0.048). DNAm was profiled in 10 high-risk 677 (677TT + 1298AA), 10 high-risk 1298
(677CC + 1298CC), and 10 reference (677CC + 1298AA) genotype placentas. Linear modeling identified no significantly
differentially methylated sites between high-risk 677 or 1298 and reference placentas at a false discovery rate < 0.05 and
Δβ ≥ 0.05 using the Illumina Infinium HumanMethylation450 BeadChip. Using a differentially methylated region analysis
or separating cytosine-guanine dinucleotides (CpGs) by CpG density to reduce multiple comparisons also did not identify
differential methylation. Additionally, there was no consistent evidence for altered methylation of repetitive DNA between
high-risk and reference placentas.
Conclusions: We conclude that large-scale, genome-wide disruption in DNAm does not occur in placentas with the
high-risk MTHFR 677TT or 1298CC genotypes. Furthermore, there was no evidence for an association of the 1298CC
genotype and only a tendency to higher 677TT in pregnancy complications of PE/IUGR. This may be due to small sample
sizes or folate repletion in our Canadian population attenuating effects of the high-risk MTHFR variants. However, given
our results and the conflicting results in the literature, investigations into alternative mechanisms that may explain the link
between MTHFR variants and pregnancy complications, or in populations at risk of folate deficiencies, are warranted.
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Background
One-carbon metabolism (OCM) is a fundamental biochem-
ical pathway that activates and transfers methyl (CH3)
groups for purine synthesis and methylation of DNA, pro-
teins, and lipids, making it important for processes such as
DNA synthesis, cellular division, and proliferation. Both
functional and dietary deficiencies are thought to contribute
to altered OCM cycling. Several B vitamins act as substrates
or cofactors for OCM, most notably vitamin B9 or folate,
the transporter of methyl groups in OCM. Genetic variants
in a central OCM enzyme, 5,10-methylenetetrahydrofolate
reductase (MTHFR), have been heavily researched in asso-
ciation with human diseases, such as cardiovascular disease,
pregnancy complications, and cancers [1–4]. MTHFR
catalyzes the irreversible reduction of 5,10-methylenetetra-
hydrofolate (5,10-CH3-THF) to 5-methyltetrahydrofolate
(5-CH3-THF). 5-CH3-THF is subsequently used as the sub-
strate for the conversion of homocysteine to methionine,
catalyzed by the enzyme methionine reductase. Methionine
is then used to synthesize S-adenosylmethionine (SAM),
the universal methyl donor for methylation reactions, in-
cluding DNA methylation (DNAm), catalyzed by DNA
methyltransferases (DNMTs). As such, MTHFR is key to
directing one-carbon units toward DNAm reactions, which
has motivated the investigation of alterations in DNAm as
the mechanism underlying the association of genetic vari-
ants inMTHFR with various pathologies.
Two single-nucleotide polymorphisms (SNPs) in the
MTHFR gene, 677C>T (rs1801133) and 1298A>C
(rs1801131), result in reduced MTHFR function in vitro,
particularly in the homozygous recessive state [5–8].
These variants are common in the population; globally,
the variant allele frequencies are approximately 0.25–0.3
(dbSNP [9]), though frequencies vary between different
populations. These variants have been associated with
markers of altered OCM, such as increased levels of
homocysteine and altered levels of blood folates [10–16],
most consistently for the 677 variant. High-risk MTHFR
genotypes (677TT and 1298CC) or variant alleles (677T
and 1298C) have been found in association with a num-
ber of reproductive and developmental pathologies.
MTHFR 677 and 1298 variants in affected pregnancies
or parents have been associated with miscarriage [17–19]
and neural tube defects [20–25]. The 677T allele and
677TT genotype in mothers have been associated with pre-
eclampsia (PE), a maternal hypertensive disorder in preg-
nancy [26–28]. Associations between fetal-placental
MTHFR 677TTgenotypes have been identified [29], though
these are not as well studied as the maternal variants.
Researchers have hypothesized that increased risk of
pathology might be attributed to aberrant patterns in
DNAm, resulting from altered OCM flux caused by
these MTHFR variants [25, 30, 31]. While several studies
have investigated the association of the MTHFR 677C>T
and 1298A>C variants with altered DNAm, results are
inconsistent; some have reported associations between
the high-risk homozygous MTHFR genotypes and/or
folate levels and altered DNAm [32–37], whereas others
find no association [38–41]. As gene expression, DNAm
patterns, and metabolic requirements are highly variable
between tissues, even these conflicting results ascer-
tained in adult, non-pregnant blood, may not generalize
to pregnancy complications.
The placenta is a directly relevant tissue in which to
study the interaction between MTHFR variants, altered
DNAm, and pregnancy complications. Due to the demand
for DNA synthesis, cellular division, and proliferation by
the growing fetus and placenta, the requirement for folate
during pregnancy increases by approximately 5–10 times
the level of non-pregnant women [42]. High-affinity folate
receptors on maternal-facing trophoblast cells allow the
placenta to transport and concentrate folate from the ma-
ternal blood up to three times within the placenta [43, 44],
ensuring the availability of this crucial nutrient during
development. Consistent with studies in other tissues, the
MTHFR 677T allele is associated with reduced MTHFR
enzyme function in the placenta [45]. If OCM flux is
impaired and DNAm patterns are altered in the placenta
due to reduced variant MTHFR function, this could have
implications for placental function and thus increase risk
of pregnancy complications. Aberrant DNAm in the form
of imprinting is known to have significant impact on
placental development (reviewed in [46, 47]). Genome-
wide or imprinted gene-specific alterations in DNAm have
been noted in placental insufficiency complications of
intrauterine growth restriction (IUGR) [48] and in early-
onset PE [49–51]. Additionally, the placenta is a tissue
that may be more likely to exhibit altered DNAm in
response to reduced MTHFR enzyme function. The
placenta exhibits a high degree of within- and between-
individual variability in DNAm [52, 53], suggesting that it
may be tolerant to changes in DNAm, allowing this organ
to adapt to environmental conditions [52–54].
To date, no studies have investigated the association
between DNAm in the placenta and the high-risk
MTHFR 677TT and 1298CC genotypes. This may pro-
vide insight in to how the MTHFR variants have been
previously associated with pregnancy complications, and
potentially help to resolve the currently conflicting
literature investigating the association between these
variants and DNAm in other tissues. In this study, we
evaluated whether fetal high-risk MTHFR genotypes
were more prevalent in pregnancy complications of PE,
IUGR, and neural tube defects (NTDs) using 303
placental DNA samples. The DNAm patterns of 30
placentas were heavily profiled using both site-specific
and genome-wide techniques, including the Illumina
Infinium HumanMethylation450 BeadChip array and
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repetitive DNA methylation, to understand the relation-
ship between high-risk MTHFR 677TT and 1298CC
genotypes and DNAm in the placenta.
Methods
Ethics and sample collection
Ethics approval for this study was obtained from the
University of British Columbia/Children’s Hospital and
Women’s Health Centre of British Columbia Research
Ethics Board (H04-70488, H10-01028). Placentas were
collected from term deliveries at BC Women’s Hospital
and Health Centre and from second trimester stillbirths,
elective terminations, and spontaneous abortions through
the embryo-fetal pathology laboratory. Cases with a pre-
natally identified chromosomal abnormality were excluded.
A minimum of two distinct sites were sampled from
the fetal side of each placenta after fetal membranes
(amnion and chorion) were removed. Samples were
washed thoroughly with PBS to remove maternal blood.
DNA was extracted by a standard salting-out procedure
modified from Miller et al. [55] and quality evaluated
using a NanoDrop ND-1000 (Thermo Scientific). One
site from each placenta was selected at random for geno-
typing. As DNAm varies significantly within the placenta
[52, 53], DNA was combined in equal amounts from at
least two sites to generate a more representative sample
in which to evaluate placental DNAm.
Case characteristics
A total of 303 placentas were screened for MTHFR 677
and 1298 polymorphisms. These included 179 placentas
from uncomplicated pregnancies, 48 from pregnancies
associated with PE (28 early-onset PE, 20 late-onset PE),
21 from pregnancies associated with intrauterine growth
restriction in the absence of maternal hypertension
(normotensive IUGR, nIUGR), and 55 from pregnancies
with a fetal NTD (Table 1). PE was defined according to
the Society of Obstetricians and Gynaecologists of
Canada (SOGC) criteria as pregnancies with (i) gesta-
tional hypertension (BP > 140/90 mmHg) and protein-
uria (> 300 g/day) arising after 20 weeks of gestation; (ii)
pre-existing hypertension with superimposed gestational
hypertension, proteinuria, and/or one or more adverse
maternal or fetal conditions; or (iii) gestational hyperten-
sion without proteinuria, with one or more adverse
maternal or fetal conditions [56]. PE was subdivided into
early-onset preeclampsia (EOPE), defined as a diagnosis
of PE before 34 weeks of gestation, and late-onset pre-
eclampsia (LOPE), a diagnosis of PE after 34 weeks of
gestation [57]. IUGR commonly co-occurs with PE and
was also defined following the SOGC criteria as birth
weight < 3rd percentile, accounting for both fetal sex
and gestational age (GA), or birth weight < 10th percent-
ile with additional clinical findings indicative of poor
growth such as uterine artery notching, absent or
reversed end-diastolic velocity on Doppler ultrasound,
or oligohydramnios [58]. nIUGR was defined as unex-
plained IUGR without the presence of maternal hyper-
tension. NTDs were defined as a fetus diagnosed with
spina bifida, anencephaly, or encephalocele on ultra-
sound and/or fetal autopsy.
MTHFR genotyping
Placental DNA was genotyped for the MTHFR 677 and
1298 polymorphisms using pyrosequencing. Primer
sequences and reaction conditions can be found in
Additional file 1: Table S1. Five microliters of PCR prod-
uct was sequenced on a PyroMark Q96 MD Pyrosequen-
cer (Qiagen) using standard protocols [59]. A subset of
the genotyping results from the NTD group (N = 36) has
been published elsewhere [60].
Population stratification
Minor allele frequencies for the MTHFR 677 and 1298
SNPs vary significantly between different populations
[61–64], as do the prevalence of NTDs and PE/IUGR
pathologies [65]. Both high-risk MTHFR genotypes vary
by ethnicity and geography, indicating that selective
pressures have influenced their frequencies [62, 66].
Therefore, prior to performing a genetic association ana-
lysis, we aimed to assess whether our pregnancy compli-
cation groups were matched for ancestry. Maternal self-
reported ethnicity was available for only 67% of cases,
and no information about the father’s ethnicity was
available. We thus used a panel of 57 ancestry-
informative marker (AIM) SNPs [67–69] that were
Table 1 Clinical characteristics of cases
N Sex; N male (% male) Gestational age (weeks); median (range) Maternal age (years); median (range)
Control 179 85 (47) 39.6 (19.4–41.9) 34.4 (23.8–42.7)
EOPE 28 17 (61) 32.7 (23.6–38.4)* 36.0 (19.7–42.9)
LOPE 20 10 (50) 38.5 (34.9–41.4)* 34.3 (26.1–41.5)
nIUGR 21 9 (42) 36.2 (24.0–40.6)* 34.5 (26.1–42.8)
NTD 55 28 (51) 21.0 (16.7–23.7)* 30.4 (17.7–40.6)*
EOPE early-onset preeclampsia, LOPE late-onset preeclampsia, nIUGR normotensive intrauterine growth restriction, NTD neural tube defect
*p < 0.05, calculated in comparison to the control group by Fisher’s exact test for categorical variables and Mann-Whitney test for continuous variables
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developed to distinguish between African, European,
East Asian, and South Asian ancestries to infer the an-
cestry of study samples and assess population stratifica-
tion along three major axes of variation.
Two hundred seventy-seven placental villus DNA
samples were successfully genotyped at 53 AIMs using
the Sequenom iPlex Gold platform by the Génome Qué-
bec Innovation Centre at McGill University, Montréal,
Canada, with a call rate > 0.9 for both SNPs and sam-
ples. Multidimensional scaling (MDS) with k = 3 dimen-
sions was performed in our study samples (N = 277) in
addition to individuals (N = 2157) from African, East
Asian, European, and South Asian populations from the
1000 Genomes Project (1kGP) [64] using 50 of the AIM
genotypes that were available in both cohorts. This
method allows 1kGP samples to be used as ancestry ref-
erence populations for our admixed population and has
been used to identify ancestry outliers [70, 71]. The first
three MDS coordinates were extracted for each sample
and used to describe ancestry along a continuum rather
than in discrete groups. We believe this better reflects
ancestry in admixed populations such as that in Vancou-
ver, as well as potentially better representing variation
within an ancestry group. Further description of this
method is included in Additional file 2: Methods.
MTHFR genotype and DNAm
To assess the association of MTHFR genotype with DNAm,
a subset of 30 control/mild pregnancy complication placen-
tas were selected for in-depth DNAm profiling, hereafter
referred to as the placental DNAm samples. None of these
placentas had chromosomal abnormalities, as confirmed by
multiplex ligation-dependent probe amplification in one or
more sites per placenta. The effect of each MTHFR SNP
was assessed independently by comparing 10 placentas with
reference genotype at each MTHFR SNP (677CC +
1298AA), 10 placentas with the high-risk 677TT genotype
in combination with the reference 1298AA (termed “high-
risk 677”), and 10 placentas with high-risk 1298CC genotype
in combination with the reference 677CC genotype (termed
“high-risk 1298”). The reference, high-risk 677, and high-
risk 1298 groups were matched by sex, gestational age, birth
weight, and maternal reported ethnicity (Table 2). To obtain
sufficient numbers in each genotype group, as the high-risk
genotypes are relatively rare in our population and we add-
itionally excluded heterozygotes at either locus, some mild
pregnancy complication cases (LOPE without IUGR and
nIUGR) were included. We previously found no evidence
for altered placental DNAm associated with these pheno-
types compared to controls in a separate study [51].
Illumina Infinium HumanMethylation450 BeadChip
Combined placental DNA from the 30 placental DNAm
samples described in Table 2 was purified using the
Qiagen DNeasy Blood and Tissue kit, and 750 ng of this
DNA was bisulfite converted using the EZ DNA Methy-
lation kit (Zymo Research) following the manufacturer’s
protocols. Samples were processed following the
Illumina Infinium HumanMethylation450 BeadChip
(450k array) protocol [72] and scanned using the Illumina
HiScan 2000. Raw intensity was read into Illumina Genome
Studio software 2011.1, and background normalization was
applied. Data processing was performed as described in
Price et al. [73], including sample quality checks, probe fil-
tering, data normalization, and batch correction. This
processing pipeline resulted in a final N = 442,355
cytosine-guanine dinucleotide (CpG) sites from the
450k array for analysis.
Repetitive DNA methylation
In addition to the 450k array, genome-wide DNAm was
also assessed using DNAm at repetitive Alu, LINE-1,
and ribosomal DNA (rDNA) sequences [74] by pyrose-
quencing in the 30 placental DNAm samples. These se-
quences are dispersed throughout the genome, allowing
DNAm to be measured at many sites using a single assay
per repetitive sequence. DNAm at these three repetitive
DNA sequences has been shown to be altered due to dif-
ferent environmental or biological factors [75–79]. Three
hundred nanograms of purified combined placental villi
DNA was bisulfite converted using the EZ DNA
Methylation-Gold Kit (Zymo Research) following the
manufacturer’s protocol. Alu and LINE-1 elements were
amplified using primer sets designed to complement the
L1H and AluSx consensus sequences [80], and rDNA
repeats were amplified using primers designed to target
the rDNA promoter [81] (Additional file 1: Table S1).
PCR products were sequenced on a PyroMark Q96 MD
Pyrosequencer (Qiagen) using standard protocols [59].
The DNAm status of each CpG dinucleotide (Alu: N = 3;
LINE-1: N = 4; rDNA: N = 26) was evaluated using the
PyroQ CpG software (Biotage). For each assay, the cor-
relation of DNAm between CpGs was confirmed, and
then an average DNAm was calculated across the CpGs
within each assay in each sample.
Statistical analyses
Statistical analyses were conducted in R statistical soft-
ware [82]. Deviation from Hardy-Weinberg equilibrium
(HWE) at the two MTHFR SNPs in controls was
assessed using an exact test for HWE. Differences in the
distribution of ancestry MDS coordinate values between
control and pregnancy complication groups (EOPE,
LOPE, nIUGR, NTD) were assessed using the
Kolmogorov-Smirnov test. The association between the
frequency of MTHFR 677TT and/or 1298CC genotypes
and pregnancy complications was assessed using a one-
tailed Fisher’s exact test to test the hypothesis that the
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high-risk genotypes will be increased in pregnancy com-
plications compared to controls. For the placental
DNAm samples, 450k array-wide average DNAm and
percent outlier probes per sample were calculated as in
Price et al. [60]. Altered measures of genome-wide
methylation, including 450k array-wide average, percent
outlier probes, Alu, LINE-1, and rDNA methylation,
were assessed using the Mann-Whitney test. All p values
from statistical tests involving multiple comparisons (an-
cestry MDS coordinate values, altered genome-wide
DNAm measures) were corrected for multiple testing
using the Bonferroni method.
450k array site-specific differential methylation was
also assessed as in Price et al. [60]. Briefly, a linear model
with the MTHFR group as the main effect and fetal sex
and gestational age included as covariates was fit to
every CpG on the array (N = 442,355). Differential
methylation results were then extracted for the compari-
son of high-risk 677 to reference and for that of high-
risk 1298 to reference. These comparisons were used to
calculate group differences in DNAm (delta-beta, Δβ).
Significantly differentially methylated CpG sites were con-
sidered as those with a false discovery rate (FDR) < 0.05
and Δβ ≥ 0.05. Two dimension-reduction techniques were
additionally used in the 450k array data: a differentially
methylated region (DMR) analysis, as in Price et al. [60],
and an assessment of differential DNAm depending on the
CpG density of the surrounding region. 450k probes were
separated into four groups based on the CpG density: high-
density islands, island shores, intermediate-density islands,
and non-islands, defined as per Price et al. [83], and the un-
adjusted p value distributions from the linear model were
assessed in each CpG density group separately.
Results
Analysis of ancestry-informative markers identifies no
significant population stratification
Prior to testing for the association of fetal MTHFR geno-
types with NTDs or PE/IUGR groups, we sought to con-
firm that these pregnancy complication groups were not
confounded with ancestry as the frequency of the
MTHFR 677 and 1298 variants varies between different
ancestry groups [61–63]. Self-reported ethnicity was
available from mothers for only 67% (203/303) of sam-
ples, which were predominately of European (Caucasian)
and East Asian ancestries. We thus described ancestry
using coordinates 1, 2, and 3 obtained through MDS of
genotypes at 50 AIMs (Additional file 3: Table S2) in
277 of our placental samples along with 2157 samples
from the 1kGP [64] (Additional file 4: Figure S1). These
three MDS coordinates were significantly different be-
tween the four major continental populations from
1kGP (Additional file 4: Figure S1). Furthermore, for
those samples for which we had both maternal reported
ethnicities in addition to AIMs (N = 181), the three an-
cestry MDS coordinates were highly concordant with
maternal reported ethnicity (Additional file 5: Figure S2).
These findings suggest that this method is adequate to
describe major patterns of genetic ancestry. There was
no significant difference in the distribution of ancestry
MDS coordinate values 1, 2, and 3 between the NTD,
PE, and nIUGR pathology groups in comparison to con-
trols (Fig. 1). We thus concluded that our pathology
groups do not show evidence of confounding by ancestry.
MTHFR 677TT and 1298CC genotypes are not significantly
associated with PE or NTDs
To investigate whether the MTHFR 677TT and 1298CC
genotypes were associated with PE, nIUGR, or NTD
pathologies, we genotyped placentas at these two loci
from 179 control, 28 EOPE, 20 LOPE, 21 nIUGR, and
55 NTD pregnancies. Neither SNP deviated from HWE
in controls (Additional file 6: Table S3). In our popula-
tion of 303 placentas collected in Vancouver, Canada,
the frequencies of the variant MTHFR 677T and 1298C
alleles were 0.295 and 0.290, respectively. There was no
significant increase in the frequency of the high-risk
MTHFR 677TT or 1298CC genotypes in EOPE, LOPE,
nIUGR, or NTD cases compared to controls (Table 3).
There was, however, a tendency for increased MTHFR
677TT genotype in placentas from pregnancies compli-
cated by placental pathologies (PE or nIUGR). When
considered together (PE or nIUGR; N = 69), the increase
in MTHFR 677TT frequency compared to controls was
nominally significant (OR = 2.53, p = 0.048).
Table 2 Clinical characteristics of placental DNAm samples
N Sex; N male
(%)
Gestational age (weeks); median
(range)
Maternal ethnicity; N
Caucasian (%)
Birth weight (SD); median
(range)
Reference (677CC + 1298AA) 10 4 (40) 39.0 (36.1–41.6) 8 (80 %) 0.055 (− 1.13–1.40)
High-risk 677 (677TT +
1298AA)
10 4 (40) 37.9 (34.6–40.3) 6 (60 %) − 0.13 (− 2.97–0.70)
High-risk 1298 (677CC +
1298CC)
10 5 (50) 39.4 (38.6–40.7) 8 (80 %) 0.005 (− 1.61–2.20)
p values were calculated in comparison to the reference group by Fisher’s exact test for categorical variables and Mann-Whitney test for continuous variables
SD standard deviation
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High-risk MTHFR 677 and 1298 genotypes are not
associated with altered genome-wide DNAm in the
placenta
Due to the central role that MTHFR plays in OCM, the
high-risk MTHFR genotypes are often hypothesized to
affect the cell’s ability to methylate DNA. We anticipated
that such effects could potentially be more pronounced
in the placenta due to its high demand for folate in preg-
nancy. We selected a subset of 30 placental samples with
no, or mild, pathology in which to profile DNAm using
both genome-wide and site-specific approaches. The
selected samples were of three MTHFR genotype groups:
(1) reference (N = 10; MTHFR 677CC + 1298AA), (2)
high-risk 677 (N = 10; MTHFR 677TT + 1298AA), and (3)
high-risk 1298 (N = 10; MTHFR 677CC + 1298CC). No
cases with high-risk genotypes at both loci were available
in our population to test.
First, these 30 placental DNAm samples were run on
the 450k array, from which several measures of DNAm
were obtained. Array-wide DNAm was calculated by
averaging of 442,355 CpG sites in each sample. This
array-wide measure of DNAm did not differ significantly
between either of the high-risk MTHFR groups and the
reference group (Table 4). Altered genome-wide DNAm
might not be a characteristic of all carriers of the
MTHFR variants; thus, we also calculated the percentage
of outlier CpG sites from the 450k array for each sample
to identify individuals exhibiting outlying patterns of
DNAm [84]. Though there was no significant difference
in outlier CpGs between the high-risk 677 and reference
group (Table 4), there was a trend for more outlying
CpG sites in the high-risk 1298 group than in the refer-
ence (Table 4, Bonferroni-corrected p = 0.058).
Next, the methylation of repetitive DNA sequences was
assessed in the 30 placental DNAm samples. Repetitive
DNAm assays target numerous sites in the genome that
are not well covered by the 450k array, and thus give an
additional measure of genome-wide DNAm. No signifi-
cant alterations in the DNAm of Alu, LINE-1, or rDNA
sequences were identified between either of the high-risk
Table 3 MTHFR 677TT and 1298CC genotypes in pregnancy complications
N 677TT frequency (N) p value† OR (95% CI) 1298CC frequency (N) p value† OR (95% CI)
Control 179 0.056 (10) – – 0.101 (18) – –
EOPE 28 0.107 (3) 0.249 2.02 (0.33–8.59) 0 (0) 1.00 0
LOPE 20 0.150 (3) 0.129 2.96 (0.48–13.1) 0.150 (3) 0.355 1.57 (0.27–6.27)
nIUGR 21 0.143 (3) 0.143 2.80 (0.45–12.3) 0.048 (1) 0.891 0.449 (0.01–3.16)
NTD 55 0.091 (5) 0.260 1.69 (0.43–5.72) 0.073 (4) 0.809 0.70 (0.16–2.27)
OR odds ratio, CI confidence intervals, EOPE early-onset preeclampsia, LOPE late-onset preeclampsia, nIUGR normotensive intrauterine growth restriction, NTD
neural tube defect
†p values, calculated by one-tailed Fisher’s exact test
Fig. 1 Distribution of ancestry derived from multidimensional scaling of AIM genotypes in control and pregnancy complication placentas. In N = 28
EOPE, N = 20 LOPE, N = 21 nIUGR, or N = 55 NTD placentas, there were no significant differences in the distribution of ancestry MDS coordinate values
compared to N = 179 controls at either of the three ancestry MDS coordinates (Kolmogorov-Smirnov tests, Bonferroni-corrected p > 0.05). This suggests
that there is no population stratification by ancestry in the groups selected for this study. EOPE early-onset preeclampsia, LOPE late-onset preeclampsia,
nIUGR normotensive intrauterine growth restriction, NTD neural tube defect
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MTHFR genotype groups and the reference genotype
group (Table 4). Slightly higher methylation was seen for
the high-risk 677 group in all comparisons, though the
range of values was similar. There was, however, a trend
for decreased LINE-1 DNAm in the high-risk 1298 group
compared to the reference group (nominal p = 0.052), but
this is not meaningful after correction for multiple com-
parisons. Overall, we find no conclusive evidence for
altered genome-wide DNAm in association with the high-
risk 677 or high-risk 1298 genotypes in the placenta using
these DNAm measures.
High-risk MTHFR 677 and 1298 genotypes are not
associated with altered site-specific DNAm in the placenta
The DNAm status of individual CpG sites targeted by
the 450k array in association with the high-risk MTHFR
genotype groups was next assessed. A linear model was
fit to each CpG site to test for differential methylation
by the genotype group, including sex and gestational age
at birth as covariates. None of the 442,355 CpG sites
was differentially methylated at a FDR < 0.05 and methy-
lation difference (Δβ) > 0.05 in either of the high-risk
MTHFR genotype groups compared to the reference
group (Fig. 2).
Following this finding, two dimension-reduction tech-
niques were utilized to explore whether identification of
differences between high-risk MTHFR groups and con-
trols in the 450k array data was limited due to a small
sample size or large number of test sites. Due to struc-
tural or functional differences, some genomic regions
may be more vulnerable to the effects of a reduced
ability to methylate DNA potentially caused by the pres-
ence of variant MTHFR enzymes. As such, 450k probes
were separated into four groups based on the CpG dens-
ity of the surrounding region: high-density islands, island
shores, intermediate-density islands, and non-islands.
Additionally, a DMR finding tool was utilized to identify
whether any DMRs existed between high-risk MTHFR
genotype placentas and controls. Unadjusted p value dis-
tributions did not show differential methylation at any of
the four CpG density groups between high-risk MTHFR
and reference placentas (Additional file 7: Figure S3),
nor were any significant DMRs identified. Given these
results, we conclude that large-scale alterations in
DNAm at CpG sites measured by the 450k array in the
placenta are not commonly associated with high-risk
677 or 1298 MTHFR genotypes in our population.
Discussion
Altered DNAm has been proposed as a mechanism
through which MTHFR 677TT and 1298CC genotypes
have been associated with pregnancy complications and
other pathologies [25, 30, 31]. In this study, we sought
to investigate alterations in DNAm in association with
high-risk MTHFR 677TT and 1298CC genotypes in the
placenta, a crucial tissue for the development of the
fetus and a healthy pregnancy. Despite deeply profiling
DNAm in N = 10 high-risk 677, N = 10 high-risk 1298,
and N = 10 reference placentas using a variety of mea-
sures, we identified no evidence for altered placental
genome-wide or site-specific DNAm in association with
high-risk MTHFR genetic variants.
Given the fundamental involvement of OCM in acti-
vating and transporting methyl units, if the variant
MTHFR alleles influence DNAm, this effect is predicted
to be widespread and not gene-specific [85]. By using
the 450k array, we interrogated DNAm at over 440,000
sites in the placental genome, assessing specific CpG
sites and also genome-wide trends. This array covers
99% of RefSeq genes and is widely dispersed across
genomic features and, therefore, can provide an accurate
reflection of genome-wide changes associated with spe-
cific genomic features or gene regulation. No significant
differences in the numerous measures of altered 450k
array genome-wide or site-specific DNAm were identi-
fied, despite additionally utilizing dimension-reduction
techniques to account for a small sample size and large
number of test sites. DNAm at repetitive DNA
sequences, including Alu and LINE-1 repetitive elements
and rDNA repeats, was also assessed, as they are not
well covered by the array, and they allow us to interro-
gate numerous locations in the genome in one pyrose-
quencing assay. The Alu and LINE-1 repetitive elements
have previously been used as surrogate measures for
genome-wide DNAm [74, 86], and all three repetitive
sequences have exhibited alterations in DNAm in certain
pathologies and in response to environmental exposures
[75–79]. Though small sample size limited our power to
detect significant differences in DNAm in this study, we
aimed to mitigate this by deeply profiling the 30
Table 4 Genome-wide measures of altered DNAm in high-risk MTHFR and reference placentas
Array-wide average DNAm (β) Outlier array sites (%) Alu DNAm (%) LINE-1 DNAm (%) rDNAm (%)
Reference (N = 10) 0.407 (0.396–0.413) 0.661 (0.262–0.993) 18.9 (17.6–21.7) 52.8 (51.0–53.8) 19.4 (11.2–30.9)
High-risk 677 (N = 10) 0.405 (0.397–0.409) 0.851 (0.262–6.357) 20.1 (15.7–21.4) 53.5 (49.8–57.6) 20.0 (8.4–28.9)
High-risk 1298 (N = 10) 0.405 (0.395–0.413) 1.14 (0.501–3.37) 19.8 (17.5–21.6) 51.0 (46.5–55.0) 22.9 (10.2–28.9)
All results are reported as median (range); p values were calculated by the Mann-Whitney test for the comparison of high-risk 677 or high-risk 1298 to the reference
group with Bonferroni correction for multiple comparisons
β beta value, rDNAm ribosomal RNA genes
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placental DNAm samples using a variety of measures of
DNAm to assess whether any differential methylation
exists in association with the high-risk MTHFR geno-
types. Our study cannot fully exclude that subtle differ-
ences in placental DNAm exist in association with high-
risk MTHFR genotypes or that a subset of at-risk placen-
tas might show changes in DNAm while the groups as a
whole did not. Despite this, the results from these nu-
merous genome-wide assays reveal that at the very least,
large magnitude and/or array-wide differential methyla-
tion does not commonly occur in association with high-
risk MTHFR genotype in the placenta.
Our study is the first that has investigated the associa-
tions between MTHFR 677 and 1298 variants and
altered DNAm in the placenta, and only the second that
has done so using a genome-wide DNAm microarray
platform. Numerous studies have investigated altered
DNAm in association with MTHFR 677 and/or 1298
variants using different measures of genome-wide
DNAm and/or targeted gene DNAm, summarized in
Table 5. Results from these various studies, mainly in
the blood, are conflicting. Certain studies have found
associations between MTHFR 677 or 1298 polymor-
phisms and altered DNAm; however, many do not find
significant associations with altered DNAm or only find
altered DNAm in the presence of low levels of OCM
nutrients (Table 5). Some of these inconsistencies may
be explained by the use of different measures of altered
DNAm (i.e., genome-wide, candidate site-specific, repeti-
tive element DNAm) between studies, lack of multiple-
test correction, use of different tissues, or inconsistencies
in accounting for confounding variables. Nonetheless,
the effect of the MTHFR 677 and 1298 variants on
DNAm is clearly complex.
Several studies reviewed in Table 5 suggest that altered
DNAm in association with MTHFR 677 and 1298
variants might only be present under limited folate
conditions [33, 35]. The presence of folate stabilizes the
variant MTHFR 677 enzyme [87], and adequate folate
attenuates the effects of high-risk MTHFR 677TT geno-
type on increased homocysteine [88, 89]. Due to the
retrospective nature of the study, we were unable to
assess folate concentrations in the placenta or maternal
blood and did not have complete information on mater-
nal folic acid supplementation. Though folate status was
unknown for the cases in this study, we assume that
most of the women in our Canadian cohort were folate-
replete due to folic acid fortification in cereal and grain,
increased literacy around healthy pregnancies, and high
uptake of gestational monitoring. Additionally, in a study
of 368 pregnant women in Toronto, Canada, with simi-
lar demographics as our population in Vancouver,
Plumptre et al. found that none of these women were
folate deficient during pregnancy, even considering that
7% of women did not take folic acid supplements [90]. It
is possible that in the presence of adequate folate levels,
the activity of the variant MTHFR 677 or 1298 enzymes
in the placentas of our study was not diminished enough
to result in a compromised OCM and altered DNAm.
Despite this potential limitation, investigating alterations
in placental DNAm in association with MTHFR variants
in a folate-replete population under the hypothesis that
this may increase risk of pregnancy complications is still
warranted. Fortification of grain products with folic acid
a b
Fig. 2 450k array-wide differential DNAm volcano plots in high-risk MTHFR 677 and high-risk 1298 placentas. Differential methylation was determined using a
linear model with the MTHFR group as the main effect and fetal sex and gestational age included as covariates. The magnitude of difference (Δβ) between
risk groups and reference group is depicted on the x-axis, and the significance of the comparison (−log10(adjusted p value)) is on the y-axis, for every CpG
tested on the 450k array (N=442,355). a Differential methylation results between high-risk 677 and reference placentas. b Differential methylation results
between high-risk 1298 and reference placentas. Neither comparison identified any CpG sites differentially methylated between the high-risk MTHFR placentas
and reference placentas. 450k array Illumina Infinium HumanMethylation450 BeadChip, FDR false discovery rate
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Table 5 Literature assessing associations between MTHFR 677 or 1298 variants and altered DNAm in healthy tissues
Study Type of DNAm assessed: specific assay Tissue Study size† Results
Studies finding associations with DNAm
Stern et al. (2000) [32] Genome-wide: radiolabeled methyl
group incorporation assay
Blood 677CC: N = 9
677TT: N = 10
677TT associated with
approximately 40% higher
[3H]-methyl acceptance
capacity than 677CC (p = 0.04),
reflecting global
hypomethylation
Castro et al. (2004) [34] Genome-wide: cytosine extension assay Blood 677CC/1298AA: N = 17
677CT/1298AA: N = 22
677TT/1298AA: N = 9
677CT/1298AC: N = 22
677CC/1298AC: N = 20
677CC/1298CC: N = 7
677TT associated with higher [
3H]-dCTP relative incorporation
compared to 677CC (p < 0.05).
677TT/1298AA and 677CC/
1298CC associated with higher
relative incorporation than
677CC/1298AA (p < 0.05)
McKay et al. (2012) [31] Genome-wide: LUMA
Candidate sites (N = 3): pyrosequencing
Umbilical
cord blood
677: N = 160
1298: N = 132
mother-infant pairs
Maternal 677T allele associated
with altered mean DNAm in
IGF2 in infant cord blood
(p = 0.017); maternal 1298C
allele associated
with altered DNAm at 1 CpG in
ZNT5 (p = 0.012) in infant
cord blood.
No associations with
genome-wide DNAm
van Mil et al. (2014) [100] Candidate sites (N = 11): MassArray
EpiTYPER
Umbilical cord
blood
677CC or 677CT:
N = 413 677TT: N = 50
Maternal 677TT genotype
associated with lower DNAm
in infant blood at candidate
CpG sites in NR3C1, DRD4,
5-HTT, IGF2DMR, H19,
KCNQ1OT1, and MTHFR genes
(p = 0.03)
Weiner et al. (2014) [36] Genome-wide: Methyl Flash
Methylated DNA Quantification Kit
Blood 677CC: N = 40
677TT: N = 40
677TT associated with
significantly lower mean DNA
methylation compared to
677CC (p = 0.0034)
Llanos et al. (2015) [37] LINE-1: pyrosequencing Female breast
tissue
1298AA: N = 73
1298AC or 1298CC: N = 45
1298C allele associated with
lower LINE-1 methylation
(OR 0.96; 95% CI 0.93–0.98)
Song et al. (2016) [101] Genome-wide: Illumina 450k array Female breast
tissue
Study population: N = 81 677T and 1298C alleles associated
with differential methylation at 5
and 3 CpGs, respectively
(unadjusted p value < 5.0 × 10−5).
No sites reached significance
at an adjusted p value < 0.05
Studies finding no association with DNAm
Narayanan et al. (2004) [38] Genome-wide: radiolabeled methyl
group incorporation assay
Blood 677CC: N = 90
677CT: N = 84
677TT: N = 25
1298AA: N = 93
1298AC: N = 77
1298CC: N = 29
No altered DNAm in association
with 677T or 1298C alleles
Jung et al. (2011) [102] Genome-wide: LC/MS Blood (Folic acid supplemented/
placebo)
677CC: N = 36/40
677CT: N = 36/34
677TT: N = 33/37
No altered DNAm between the
3-year folic acid-supplemented
(0.8 mg/day) group and placebo
group and no difference in
DNAm when stratified by the
MTHFR 677 genotype
Gomes et al. (2012) [39] Genome-wide: IMDQ kit Blood 677CC: N = 72
677CT: N = 39
677TT: N = 12
No altered DNAm between
MTHFR 677 genotype groups
Ono et al. (2012) [103] Genome-wide: LUMA Blood 677CC: N = 112
677CT or 677TT: N = 272
No altered DNAm in association
with MTHFR 677 or 1298 variants
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Table 5 Literature assessing associations between MTHFR 677 or 1298 variants and altered DNAm in healthy tissues (Continued)
Study Type of DNAm assessed: specific assay Tissue Study size† Results
1298AA: N = 254
1298AC or 1298CC: N = 130
No interaction between
genome-wide DNAm, folate
intake, and MTHFR 677 or
1298 variants
Hanks et al. (2013) [104] Genome-wide: LC/MS
Candidate sites (N = 7): pyrosequencing
Colon 677CC: N = 185
677CT: N = 119
677TT: N = 32
No difference in DNAm
between MTHFR 677 genotype
groups, even when accounting
for folate biomarkers
No significant difference in
DNAm at ESR1, MYOD1, IGF2,
N33, MLH1, MGMT, and APC
genes by the genotype group
de Arruda et al. (2013) [40] Genome-wide: IMDQ kit Oral
epithelial
cells
677CC: N = 17
677CT: N = 19
677TT: N = 8
No difference in DNAm between
MTHFR 677 genotype groups
Deroo et al. (2014) [105] LINE-1: pyrosequencing Blood Study population: N = 646
women without breast
cancer
N = 294 with breast cancer
677 or 1298 genotypes not
associated with altered LINE-1
DNAm in women without
breast cancer
Louie et al. (2016) [106] Candidate sites (N = 3): bisulfite
sequencing
Sperm 677CC: N = 21
677CT: N = 19
677TT: N = 4
677 genotype not associated
with altered DNAm at MEST,
H19, or IG-GTL2 imprinted
differentially methylated regions
Wang et al. (2016) [41] Meta-analysis 11 studies 677: N = 1147
1298: N = 1053
No altered DNAm associated
with 677T and 1298C alleles
Studies finding association with DNAm only with interaction with altered OCM nutrient status
Friso et al. (2002) [33] Genome-wide: LC/MS Blood 677CC: N = 187
677TT: N = 105
677TT associated with
approximately half the mean
level of mCytosine than in the
677CC group (p < 0.0001).
This effect was driven by TT
individuals with low-folate status
Shellnut et al. (2004) [107] Genome-wide: radiolabeled methyl
group incorporation assay and LC/MS
Blood 677CC: N = 22
677TT: N = 19
No significant difference in
DNAm between 677TT and
677CC groups.
In response to 7-week folate
repletion following 7-week folate
depletion, significantly increased
mean % change and raw change
in DNAm in 677TT individuals
(p= 0.04 and 0.03, respectively)
Friso et al. (2005) [35] Genome-wide: LC/MS Blood 677CC/1298AA: N = 19
677TT/1298AA: N = 72
677CC/1298CC: N = 42
In the presence of low folate,
1298AA associated with lower
genome-wide DNAm compared
to 1298AC or 1298CC genotypes
(p=0.0001 and p=0.021,
respectively), and 677TT/1298AA
associated with lower DNAm
compared to 677CC/1298AA
(p<0.05) and 677CC/1298CC
(p<0.0001).
In 677TT/1298AA individuals,
DNAm significantly reduced in
low-folate vs high-folate
individuals (p < 0.0001)
Axume et al. (2007) [108] Genome-wide: cytosine extension assay Blood 677CC: N = 14
677CT: N = 12
677TT: N = 17
677TT associated with lower
DNAm compared to 677CC
(p < 0.05) after 7-week folate
restriction followed by 7-week
folate repletion treatment
La Merrill et al. (2012) [109] Genome-wide: LUMA 677CC: N = 31
677CT or 677TT: N = 164
677T or 1298C alleles not
associated with altered
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has not entirely reduced the incidence of NTDs in
folate-replete populations [91, 92]; in Canada, NTDs are
the most common congenital abnormality [93]. Add-
itionally, pathologies such as PE and IUGR are also
present at a high frequency in folate-replete populations,
and associations between PE and MTHFR have been
observed in such populations [27], indicating a mechan-
ism for association with pathology beyond low-folate/
folic acid status.
In our study population, we found no significant associ-
ation of NTDs, EOPE, LOPE, or nIUGR with high-risk
677TT or 1298CC placental genotypes, although there was
a tendency to increased MTHFR 677TT in pregnancies af-
fected by PE or IUGR as a whole (OR 2.53, p = 0.048). This
trend is consistent with the literature noting an increased
risk of PE in association with the 677T allele in both the
maternal blood and the placenta [27, 29]. In a recent meta-
analysis of 52 different studies, with a combined total of
7398 PE cases and 11,230 controls, Wu et al. identified a
significantly increased risk of PE in association with the
MTHFR 677T allele [28]. However, in 1103 cases and 988
controls, no association between the MTHFR 1298C allele
and PE [28] was found. As for NTDs, our data was not sug-
gestive of any association with fetal MTHFR 677TT or
1298CC genotype. Sample size limited our power to detect
significant differences between study groups; however, few
studies have investigated associations between placental/
fetal MTHFR variants and PE/IUGR and NTD pathologies
in the Canadian population post-folic acid fortification, and
the main focus of the current research was to assess altered
placental DNAm in association with high-risk MTHFR
genotypes. Larger studies in NTDs have identified
increased risk in association with the 677 variant [25], but
there is inconsistent evidence for an association with the
1298CC genotype [24, 94].
Population stratification, the presence of systematic
differences in allele frequencies between cases and con-
trols, typically due to differences in ancestry, can be a
limitation of genetic or epigenetic association studies.
Specifically, false positive or negative results can be a
consequence of failing to match study groups on this
variable. To address this, we utilized a novel approach to
assess population stratification in our study groups using
three continuous variables of ancestry based on a MDS
analysis of a panel of AIMs. This is similar to studies
using MDS of genome-wide genotypes (i.e., from a SNP
array or DNA sequencing) in study samples combined
with ancestry reference populations to identify ancestry
outliers, select homogeneous groups, or infer ancestry
[70, 71, 95], and to studies that include principal compo-
nents or MDS coordinates highly associated with ances-
try in statistical models to correct for ancestry [96, 97].
Other potential confounding factors for our study, such
as maternal smoking status, diet, and medications taken
during pregnancy, were not well documented in all cases
included in this study and thus could have resulted in
heterogeneity between study groups that we were unable
to account for in statistical modeling.
Currently, the evidence supporting the relationship
between MTHFR 677 or 1298 variant and pathology
or altered DNAm is not conclusive enough for physi-
cians to support implementing MTHFR genetic testing
as a clinical practice [98]. Despite this, MTHFR geno-
typing is available from 50 certified labs in the USA
[98], and testing is widely promoted in the naturo-
pathic field, where patients are told that a “faulty
genotype” may explain a list of symptoms and dis-
eases including “anxiousness, adrenal fatigue, brain
fog, cervical dysplasia, increased risk of many cancers,
low thyroid, leaky gut, high blood pressure, heart
Table 5 Literature assessing associations between MTHFR 677 or 1298 variants and altered DNAm in healthy tissues (Continued)
Study Type of DNAm assessed: specific assay Tissue Study size† Results
Blood
(pregnant
women)
1298AA: N = 158
1298AC or 1298CC: N = 37
genome-wide DNAm, but
vitamin B6 deficiency and
presence of 677T allele
associated with hypomethylation
(p= 0.02)
Aarabi et al. (2015) [110] Genome-wide: RRBS
Candidate sites (N = 6): pyrosequencing
Sperm 677CC: N = 13
677CT or 677TT: N = 17
After 6 months of high-dose
folic acid supplementation,
there was significant reduction
in methylation in intergenic
regions in 677CC men, whereas
677CT or 677TT men had
significantly reduced
methylation in promoters, exons,
introns, and intergenic regions
(p< 0.05)
LUMA luminometric methylation assay, LINE-1 LINE-1 repetitive elements, LC/MS liquid-chromatography tandem mass spectrometry, IMDQ imprint methylated
DNA quantification
†Sample size given for each MTHFR SNP was assessed in publication. If the sample size of specific genotypes is not present, it was not reported in publication. The
combined MTHFR 677/1298 genotypes are specified when available; otherwise, these SNPs were assessed independently from one another in the same
sample population
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attacks, stroke, Alzheimer’s disease, diabetes, and miscar-
riages” (https://sciencebasedmedicine.org/dubious-mthfr-
genetic-mutation-testing/). These patients are advised to
take supplements containing “methyl folate” and “methyl
B12” to increase methylation and decrease their risk of dis-
ease development (https://www.jillcarnahan.com/2013/05/
12/mthfr-gene-mutation-whats-the-big-deal-about-methy-
lation/). Our findings, coupled with variable results from
other studies, suggest that these variants may not be of
such strong concern in terms of DNAm, particularly in
healthy individuals meeting folate requirements; however,
studies with larger sample sizes are required to validate this.
At the very least, the negative results from our study sug-
gest that if these variants have an effect on placental and
thereby newborn health in Canada, it may not be through
altered DNA methylation.
Conclusions
DNA methylation (DNAm) alterations have been pro-
posed to be the link between MTHFR 677C>T and
1298A>C variants and increased risk of pregnancy compli-
cations. In this novel study of DNAm in human placentas
of high-risk MTHFR 677TT and 1298CC individuals, we
did not find evidence of altered DNAm associated with
these genotypes in numerous measures of genome-wide
and CpG site-specific methylation. We conclude that
widespread changes in DNAm do not occur in the placen-
tas of MTHFR 677 and 1298 variant carriers in our folate-
replete population. Further studies with larger sample
sizes and/or in populations that are folate deficient may
support or refute our results. The results from this study
suggest that factors other than alterations in DNAm may
contribute to the previously reported association between
high-riskMTHFR genotypes and pathology.
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